Randomized Phase II study of SOX vs mFOLFOX6 as neoadjuvant chemotherapy in patients with resectable rectal cancer (KSCC1301)
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2019
Price : $35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Fluorouracil; Folinic acid
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- 01 Mar 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 02 Jun 2017 Results assessing efficacy and safety presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.